TRGNF:OTC-Transgene SA (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.59

Change

0.00 (0.00)%

Market Cap

USD 0.21B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

-2.01 (-2.14%)

USD 34.52B
UCBJF UCB SA

N/A

USD 33.97B
ARGNF argenx SE

N/A

USD 32.04B
GNMSF Genmab A/S

-2.20 (-0.93%)

USD 16.79B
ZLDPF Zealand Pharma A/S

-7.00 (-5.30%)

USD 9.62B
IVBIY IVBIY

N/A

USD 8.92B
SBMFF Sino Biopharmaceutical Limited

+0.04 (+9.81%)

USD 7.86B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.85B
WXIBF WuXi Biologics

N/A

USD 7.06B
WXXWY WuXi Biologics (Cayman) Inc

+0.16 (+4.65%)

USD 7.06B

ETFs Containing TRGNF

BIS ProShares UltraShort Nasd.. 2.25 % 0.95 %

-0.25 (-1.61%)

USD 3.21M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.85% 60% D- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.85% 60% D- 47% F
Trailing 12 Months  
Capital Gain -14.05% 61% D- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.05% 61% D- 41% F
Trailing 5 Years  
Capital Gain -16.75% 71% C- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.75% 71% C- 51% F
Average Annual (5 Year Horizon)  
Capital Gain 2,240.23% 95% A 97% N/A
Dividend Return 2,240.23% 95% A 97% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5,664.23% 8% B- 4% F
Risk Adjusted Return 39.55% 90% A- 76% C+
Market Capitalization 0.21B 81% B- 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector